Para‐aortic Lymphadenectomy after Chemotherapy for Metastatic Non‐seminomatous Germ Cell Tumours: Prognostic Value and Therapeutic Benefit
W. F. HENDRY(HealthPartners), A. Horwich(Institute of Cancer Research), John Hetherington(Royal Marsden NHS Foundation Trust), Roger A’Hern, D.P. Dearnaley(Royal Marsden NHS Foundation Trust), Michael Peckham(Royal Marsden Hospital)
Cited by 104
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
|Journal of Clinical Oncology|2003|548
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
|Journal of Clinical Oncology|1997|334
Oxford textbook of oncology
|Biomedicine & Pharmacotherapy|1996|299